Home MarketDivi's Laboratories Ltd.

Divi's Laboratories Ltd. Stock Info: As on 2017-09-22 15:59:48

Nse

970.25

-20.65(-2.08%)
Change%
52 Week Range
532.65
29.00
1,351.35
26.00
Open997.10
Day's Range891.81 - 1,089.99
Value Traded (in ₹ Cr.) 707.54

Bse

969.00

-21.90(-2.21%)
Change %
52 Week Range
533.10
29.00
1,349.95
26.00
Open995.05
Day's Range891.81 - 1,089.99
Value Traded (in ₹ Cr.) 63.25

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 50,000.00 0.02%
IndianPromoters 138,181,232.00 52.05%
Mutual Funds/UTI 36,504,582.00 13.75%
FII 45,717,679.00 17.22%
Employee 0.00 0.00%
Public 25,986,597.00 9.79%
Government 0.00 0.00%
Others 17,829,140.00 6.72%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 7.03
Basic EPS (Rs.) 41.73
Cash EPS 46.17
BVPerShare Excl 163.87
Operating Revenue 140.18
PBDITPerShare 56.21
Dividend 10.00
NPPerShare 41.73
Current Ratio 6.04
Quick Ratio 3.79
PriceToBV 6.01
Earnings 0.04
PBDIT Margin 40.10
PBT Margin 36.86
NP Margin 29.76
Return On Assets 22.03
Retention Ratios 76.03
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 3,815.73
Total Expenses 2,443.89
EBITDA 1,492.26
PBT 1,371.84
PAT 1,107.69
Net Income 1,107.69
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,980.80
Total Expenses 1,287.13
EBITDA 634.56
PBT 691.91
PAT 568.78
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 53.09
Net worth 4,350.14
Investments 805.35
Total Liability 5,027.50
Total debt 41.89
Net block 1,702.55
Total Assets 5,027.50
Parameter Sep-16 (₹ Cr.) 6M % change
Total share capital 53.09
Net worth 4,100.87
Investments 662.79
Total Liability 4,761.28
Total debt 36.68
Net block 1,590.62
Total Assets 4,761.28
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

526.85 535.6 -1.63
524544.45

Abbott India Ltd.

4252.9 4252.25 0.02
40014269

Ajanta Pharma Ltd.

1208.5 1256.6 -3.83
11881297.65

Albert David Ltd.

287.8 292.5 -1.61
282.5300.9

Alembic Ltd.

40.2 43.1 -6.73
38.1544.7

Alembic Pharmaceuticals Ltd.

489.95 500.35 -2.08
475.1504

Alkem Laboratories Ltd.

1800.95 1801.2 -0.01
17341819
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

103.15 101.05 2.08
90121.8

Aarti Drugs Ltd.

524.5 533.85 -1.75
524.5540

Aayush Food & Herbs Ltd.

48.55 48.55 0
48.5548.55

Abbott India Ltd.

4164 4269.8 -2.48
40354275

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 1,032.40
Cash from investing activities -413.43
Cash from financing activities -624.14
Net change in cash -5.17

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Reliance Equity Opportunities Fund 3.60%
SBI Magnum Balanced Fund 2.13%
HDFC Mid-Cap Opportunities Fund - Regular Plan 0.83%
SBI Blue Chip Fund 0.94%
Reliance Pharma Fund 9.53%
SBI Emerging Businesses Fund 6.42%

SAIL eyes higher market share on surging steel demand: Chairman

Armed with latest technologies and higher product mix, SAIL aims to tap big into the steel demand in India, which is projected to become the fifth- largest economy this year, its Chairman P K Singh said. Addressing the 45th annual general meeting of the state- owned Steel Authority of India Ltd (SAIL) here, Singh said the steel demand in India will witness a significant growth in future, given the current stage of development in Indian economy. The World Steel Association, in its short range outlook, has forecast 6.1 per cent growth in steel consumption for India in 2017, the SAIL chief added. According to Singh, the domestic steel demand is improving on the back of government policies and developmental goals, and SAIL is expeditiously equipping itself to serve market requirements fully and claim a broader market share. SAIL with newer and better technologies at its disposal aims to leverage potential of growth in steel demand by operating at rated capacities, product differentiation and customer satisfaction, Singh said. The chairman also shared the company's efforts towards product value addition. SAIL has done significant value addition in its product mix, with higher grades of steel... from Rourkela Steel Plant's new plate mill for the oil and gas sector, SAIL HT-600 for the automotive sector and high strength LPG steel grade from Bokaro Steel Plant, etc, Singh said. At Bhilai Steel Plant (BSP), the world's longest single piece rail of 130 metres is being produced and supplies of welded 260 metres rail panels to the Indian Railways are in progress. Besides, a 3 mtpa hot strip mill in Rourkela is slated to be installed by 2018. He further said, World economic recovery is on track... and presents a healthy sign for industrial and manufacturing activities across globe. India is projected to become the world's fifth-largest economy in 2017, surpassing UK and France and the world's third largest economy by 2023, surpassing Japan and Germany. Such kind of growth will definitely create larger steel demand and boost consumption in country, the chairman added. Listing out the achievements of SAIL, Singh said the company since inception has produced 475 million tonnes (mt) of crude steel and partnered in all major national projects requiring steel. The company is also taking initiatives towards remodelling its operations.

22-09-2017 16:49

PNB plans to raise up to Rs 5000 cr from markets

Punjab National Bank today said it plans to raise up to Rs 5,000 crore equity capital from the markets to fund growth. The public sector bank however did not give any indication as to whether it would be raised by diluting government equity or issuing Additional Tier-1 (AT1) bonds. The decision in this regard would be taken in the board meeting on September 27, PNB said in a filing to the stock exchanges. The bank would consider raising common equity Tier capital up to Rs 5,000 crore as per Basel III requirements, it said. PNB had reported over 12 per cent rise in net profit at Rs 343.40 crore for the quarter ended June 30, 2017. Total income of the bank rose to Rs 14,468.14 crore in the said quarter from Rs 13,475.41 crore a year ago. With regard to assets metrics, the bank's gross non- performing assets (NPAs) declined marginally to 13.66 per cent of gross advances as on June 30, 2017 from 13.75 per cent a year ago. Meanwhile, shares of the Bank closed trading at Rs 137.80 apiece, down 2.92 per cent from the previous close on BSE.

22-09-2017 15:47

SBI's new index at LSE to help investors track Indian bonds

State Bank of India, in partnership with FTSE Russell, brought out a new index series at the London Stock Exchange to enable investors and market participants to track Indian bond movement. FTSE Russell is a global data and analytics provider. The FTSE SBI Bond Index Series demonstrates SBI's commitment to play befitting leadership role in development of India's bond market, State Bank of India (SBI) said in a statement. We have teamed up with FTSE Russell to launch the FTSE- SBI Bond Index Series. This index will act as a key benchmark for Indian debt for foreign investors looking to invest in Indian debt market, SBI Chairman Arundhati Bhattacharya said in the statement. It will significantly contribute to development and broadening of the Indian bond market, Bhattacharya hoped. The index series, SBI said, provides the global investor community and other market participants the tools they need to analyse India's bond market. The launch follows the November 2015 visit of Prime Minister Narendra Modi in the UK when a letter of intent was singed between SBI and FTSE to jointly develop the new index tracking Indian fixed income securities. This initiative was also announced as a priority under the India UK Financial Partnership (IUKFP), SBI said further. Today's launch of this innovative index series demonstrates SBI's commitment to play befitting leadership role in development of India's bond market. This index is also an important enabler of India-focused funds and is expected to facilitate investment flows, the bank said. Meanwhile, shares of the Bank closed trading at Rs 261.90 apiece, down 2.46 per cent from the previous close on BSE.

22-09-2017 15:44

Adhunik Industries hits 52 week low on SAT order

Shares of Adhunik Industries plunged 20 per cent, hitting 52-week low, on the Bombay Stock Exchange after the Securities Appellate Tribunal (SAT) directed the market regulator to reverse their decisions all dated August 7, 2017 qua the appellant forthwith. According to data available with exchange, as much as 792 lakh shares changed hands over-the-counter as compared to two week average of 1.54 lakhs. Weighed down by the development, shares of the company declined as much as 20 per cent to hit 52-week low of Rs 83.55 apiece on the Bombay Stock Exchange. The stocks were currently trading at Rs 83.55 against previous close price of Rs 104.40. In a similar fashion, shares of the company were trading 19.98 per cent lower at Rs 79.10 apiece on the National Stock Exchange. Meanwhile, the broader benchmark BSE Sensex was trading at 31,944.47, down 425.57 points, or 1.30 per cent, at 14:45 hours.

22-09-2017 14:57

Dabur India joins hand with Amazon for ayurveda marketplace

Homegrown FMCG major Dabur India today said it has tied up with e-commerce major Amazon for an online ayurveda marketplace which will house all ayurvedic brands and products available in the country. The company, which will also offer consumers an insight into various ayurvedic medicines for treating a variety of ailments, said the idea is to service all health and personal care related needs of patients. The exclusive ayurveda e-marketplace has been hosted by Amazon India and the content is developed by Dabur India, the company said in a statement. Consumers can search basis companies, brands and ailments and will gain access to all ayurveda solutions available in the country today, Dabur India Executive Director Consumer Care Business KK Chutani said. Products of other ayurvedic manufacturing companies like Baba Ramdev-promoted Patanjali and Himalaya would also feature on the marketplace. By providing A+ content for developing this marketplace, Dabur also gains prime visibility on the portal, Chutani said. Meanwhile, shares of the company were trading at Rs 305.70 apiece, down 1.51 per cent from the previous close at 14:50 hours on BSE.

22-09-2017 14:48

Divi's Lab extends rally on successful USFDA inspection

Shares of Divi's Laboratories continued gaining streak for the second day on Thursday and added another 6 per cent on the Bombay Stock Exchange after the drug maker said that all the previous observations by US drug regulator regarding Unit-2 of its Visakhapatnam facility have been confirmed as completed and resolved. The Unit has been inspected by US-FDA from September 11 to September 19, 2017. Following the announcement, shares of the company gained as much as 5.84 per cent to trade at intra-day high of Rs 997.90 apiece on the Bombay Stock Exchange. In a similar fashion, shares of the company were trading 3.86 per cent higher at Rs 979.20 apiece on the National Stock Exchange. Meanwhile, the broader benchmark BSE Sensex was trading at 32,273.56, down 126.95 points, or 0.39 per cent, at 11:30 hours.

21-Sep-2017 11:30 AM

Divi’s Labs unit-2 completes USFDA inspection

Divi’s Laboratories said that all the previous observations by US drug regulator regarding Unit-2 of its Visakhapatnam facility have been confirmed as completed and resolved. “Unit-2 has been inspected by the U.S. Food and Drug Administration (US-FDA) from September 11 to September 19, 2017. This inspection was for full cGMP and verification of all corrective actions proposed against the previous Inspection observations,” Divi’s Laboratories said in a BSE filing. The company announced that all previous observations have been confirmed as completed and resolved, it added. On completion of this inspection, Divi's Laboratories has received a Form 483 citing six observations which are procedural and the company will be responding to these within the stipulated time. Meanwhile, shares of the company were trading at Rs 914.95 apiece, up 5.92 per cent from the previous close at 11:45 hours on BSE.

20-Sep-2017 11:43 AM

Divi's Laboratories jumps 6% on successful USFDA inspection

Shares of Divi's Laboratories jumped over 6 per cent on the Bombay Stock Exchange after the drug maker said that all the previous observations by US drug regulator regarding Unit-2 of its Visakhapatnam facility have been confirmed as completed and resolved. The Unit has been inspected by US-FDA from September 11 to September 19, 2017. Following the announcement, shares of the company gained as much as 6.44 per cent to trade at intra-day high of Rs 919.50 apiece on the Bombay Stock Exchange. In a similar fashion, shares of the company were trading 5.72 per cent higher at Rs 912.65 apiece on the National Stock Exchange. Meanwhile, the broader benchmark BSE Sensex was trading at 32,421.94, up 19.57 points, or 0.06 per cent, at 11:45 hours.

20-Sep-2017 11:40 AM

Divi's Lab - Updates

Divi''s Laboratories Limited has informed the Exchange regarding ''We wish to inform that Divi?s Laboratories Limited, Unit-2 has been inspected by US-FDA from September 11 to September 19, 2017.This inspection was for full cGMP and verification of all Corrective Actions proposed against the previous Inspection observations. Divi?s Laboratories Limited announces that all previous observations have been confirmed as completed and resolved. On completion of this inspection, Divi?s Laboratories Limited has received a Form 483 citing six observations which are procedural and the company will be responding to these within the stipulated time.Disclaimer:This is to inform that the statements in this document relating to the estimates or events may be ?forward looking statements? within the meaning of the applicable securities regulations. Actual results, performance or events, financial or non-financial, could differ materially from those expressed or implied.''.

20-Sep-2017 10:52 AM

Divi's Lab - Updates

We wish to inform that Divi's Laboratories Limited, Unit-2 has been inspected by US-FDA from September 11 to September 19, 2017.

This inspection was for full cGMP and verification of all Corrective Actions proposed against the previous Inspection observations. Divi's Laboratories Limited announces that all previous observations have been confirmed as completed and resolved.

On completion of this inspection, Divi's Laboratories Limited has received a Form 483 citing six observations which are procedural and the company will be responding to these within the stipulated time.

Disclaimer:
This is to inform that the statements in this document relating to the estimates or events may be 'forward looking statements' within the meaning of the applicable securities regulations. Actual results, performance or events, financial or non-financial, could differ materially from those expressed or implied.

20-Sep-2017 10:34 AM

Divi's Lab - Updates

We wish to inform that Divi's Laboratories Limited, Unit-2 has been inspected by US-FDA from September 11 to September 19, 2017.

This inspection was for full cGMP and verification of all Corrective Actions proposed against the previous Inspection observations. Divi's Laboratories Limited announces that all previous observations have been confirmed as completed and resolved.

On completion of this inspection, Divi's Laboratories Limited has received a Form 483 citing six observations which are procedural and the company will be responding to these within the stipulated time.

Disclaimer:
This is to inform that the statements in this document relating to the estimates or events may be 'forward looking statements' within the meaning of the applicable securities regulations. Actual results, performance or events, financial or non-financial, could differ materially from those expressed or implied.

20-Sep-2017 10:34 AM

Divi's Lab - Updates

We enclose herewith Notice of the 27th Annual General Meeting of the Company scheduled to be held on Monday, the 25th day of September 2017 at 10.00 A.M. at Global Peace Auditorium, Brahma Kumaris, Shanti Sarovar, Academy for Better World, Gachibowli, Hyderabad - 500 032.

30-Aug-2017 10:25 AM

Divi's Lab - Fixes Book Closure for Dividend & AGM

Divis Laboratories Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 19, 2017 to September 25, 2017 (both days inclusive) for the purpose of Payment of Dividend & 27th Annual General Meeting (AGM) of the Company to be held on September 25, 2017.

The dividend, if declared at the Annual General Meeting, will be credited / dispatched on or before October 10, 2017.

22-Aug-2017 12:40 PM

Corporate Details

About Management

Milestones: 1990 -Divis Research Center (DRC) established. 1991-1993 -DRC successfully develops several commercial processes for intermediates and bulk actives and supplies to manufacturing majors. 1994 -Divis Research Center changes its name to Divis Laboratories Limited to reflect its growing area of operations and its plans to enter the manufacturing sector in the following year. 1995 -Manufacturing Facility (Unit-1) at Choutuppal near Hyderabad starts operations. 1997 -SGS-Yarsley of U.K certifies Divis Laboratories as ISO-9002 compliant. 1999 -European Directorate gives a "Certificate of Suitability" (CoS) for Naproxen produced at Divis Laboratories. 2000 -US-FDA inspects Divis Laboratories successfully SGS-Yarsley of U.K awards Divis the ISO 9001 Certification SGS International AG of Switzerland awards Divis the ISO-14001 Certification (for its efficient Environment Management Systems). 2001 -BVQI of London awards Divis the OHSAS-18001 Certification (for its Occupational Health and Safety Management Systems). 2002 -Divis commences the setting up of its 2nd Manufacturing Facility (Unit-2) at Chippada near Visakhapatnam. 2003 -Divis opens a new research center christened `DRC-Vizag' for fundamental research in selected niche business core segments. -Went for IPO and listed on stock exchanges BSE, NSE and HSE. -Divi's Laboratorie receives Certificate of Substantiability from the council of Europe -Appointed Mr A Narendra as Company Secretary & Compliance Officer of the company (in place of outgoing Company Secretary Mr P Sudarshan) who has joined the organization. 2004 - Divi'S Laboratories Limited has informed that the manufacturing facility of Divi's Labs at Choutuppal near Hyderabad was successfully inspected by US-FDA in May 2004. -US-FDA inspects the Choutuppal (Unit-1) for a second time. No 483. 2006 -Delists equity shares form The Hyderabad Stock Exchange Ltd (HSE), Hyderabad with effect from March 29, 2006. -US-FDA inspects the Visakhapatnam(Unit-2) for the first time. 2007 - The Company has splits its face value from Rs10/- to Rs2/-. 2008 -Third US-FDA inspection for Choutuppal(Unit-1). 2009 - Certified and Awarded for "Best Green Belt Development" - SURAKSHA PURASKAR for the year 2008 - ISO 14001: 2004 (Re-Certification) "Environment Management System" -Divi's Laboratories has given the Bonus in the Ratio of 1:1 2010 - Divis Lab - Setting up of a new Unit in SEZ at Visakhapatnam. - The Company has recommended a dividend of 300% i.e. Rs. 6/- per equity share of Rs. 2/- face value for the year ended March 31, 2010. 2011 - Divi’s Laboratories surged 3.5 per cent in early morning trade on Bombay Stock Exchange on November 2, 2011, after the announcement of healthy growth in Q2 numbers on November 1, 2011, after trading hours. - Shares of the company after opening higher at Rs 765 from previous close of Rs 759.20, rose to hit a high of Rs 785.40 on BSE, reflecting the gain of 3.5 per cent. At 11:05 AM, the stock was trading at Rs 772.85 on Bombay Stock Exchange. 2012 - Divis Laboratories Ltd has informed BSE that the Board of Directors through Circular resolution dated March 07, 2012 has decided to seek shareholders approval by postal ballot for Re-appointment and revision in remuneration of Mr. Madhusudana Rao Divi as Director-Projects of the Company. - The Company Re-appointment and revision in remuneration of Mr. Kiran S. Divi Director & President- Operations of the Company. - Enhancement of remuneration of Dr. Murali K. Divi, Chairman & Managing Director of the Company. - Enhancement of remuneration of Mr. N. V. Ramana, Executive Director of the Company. 2013 -Divis Laboratories Ltd. has recommended a dividend of 750% i.e. Rs. 15/- per equity share of Rs. 2/- face value for the year ended March 31, 2013. 2014 -Divis Laboratories Ltd. has recommended a dividend of 1000% i.e. Rs. 20/- per equity shares of Rs. 2/- face value for the year ended March 31, 2014. 2015 -Divis Laboratories Ltd has approved to give bonus shares on the eve of 25th year of formation of the Company, in the ratio of 1:1. 2016 -Divis Labs unit-2 at Chippada successfully inspected by USFDA

Registered Office

DSN SEZ Unit : Chippada Village, Bheemunipatnam Mandal,

,,,      ,

Registrar Details

Karvy Computershare Private Ltd.